Hot off the presses, we’ve got exciting new clinical trial data regarding bictegravir/lenacapavir, an experimental two-drug regimen for people with significant HIV treatment experience. But the data we’ve received are sparse—and they come from a brief press release, not a published, peer-reviewed manuscript.
What should we make of this potentially confusing scenario? From our standpoint, the initial news is encouraging—but there’s also reason for clinicians to take these results with a grain of salt until they can see a more robust presentation of the study’s construction and findings.
Read an expert analysis from Benjamin Young, M.D., Ph.D. at TheBodyPro.
Source : TheBodyPro
Related HIV and Co-Infections News
-
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial
-
New data from EACS 2025 on quality of life and comorbidities in people with HIV
-
IDWeek 2025: Real-world findings show lenacapavir effective in highly treatment-experienced people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.